Louis Lange
Partner @ Asset Management Ventures (AMV)
Palo Alto, United States
Louis Lange is a seed investor at Asset Management Ventures (AMV) in Palo Alto focused on Health Care and Biotechnology. Louis Lange - Partner @ Asset Management Ventures (AMV)
- Total investments:
- 14
- Last investment:
- Lead investor:
- 7%
Last updated:
For AI agents: llms.txt
Industries Louis Lange invests in
Stages Louis Lange invests in
Countries Louis Lange invests in
Investment Focus
Industry
- Health Care 7 (50%)
- Biotechnology 6 (43%)
- Medical 4 (29%)
- Genetics 3 (21%)
- Pharmaceutical 3 (21%)
Stage
- Seed 3 (21%)
- Funding Round 3 (21%)
- Series A 2 (14%)
- Series B 1 (7%)
- Series C 1 (7%)
Country
- United States 7 (50%)
- Ireland 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Aegis Surgical
|
Aegis Surgical Limited will facilitate less invasive placement of aortic valves compared to open heart surgery, on an out-patient basis. | Convertible Note / Sep 17, 2019 | |
|
Aegis Surgical
|
Aegis Surgical Limited will facilitate less invasive placement of aortic valves compared to open heart surgery, on an out-patient basis. | Convertible Note / Nov 28, 2017 | |
Indi Molecular
|
Indi Molecular is an emerging life sciences company that is developing a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. PCCs were created in collaboration with the California Institute of Technology using “click chemistry,” a synthetic process that allows scientists topermanently join (“click”) together molecular components with remarkable precision and stability. PCCs offer the promise of improved selectivity, superior binding affinity, fully synthetic composition and a vastly low molecular weight compared to monoclonal antibodies, the current standard for identifying biomarkers in most diagnostics platforms – and in many therapeutic uses.The company launched as a spinout from its parent company Integrated Diagnostics (Indi) in 2013 with a $1.5 million seed round led by InterWest Partners together with several angel investors. | $11.5M / Series A / Jun 29, 2017 | |
Amygdala Neuroscience
|
Amygdala Neurosciences is developing ANS-6637 a new chemical entity with a novel MOA for treating substance use disorder. Based on a mechanism of action in the brain (published in Nature Medicine) that prevents pathophysiologic dopamine surge without changes to basal dopamine, ANS-6637 has the potential to prevent drug seeking behavior, craving andrelapse. In pre-clinical studies, ALDH2 inhibition reduced self-administration, cue- and drug-primed relapse in nicotine, alcohol, cocaine, heroin, methamphetamine and binge eating models and also demonstrated anxiolytic properties in models of stress. ANS-6637 has completed extensive Phase 1 studies and is ready for Phase 2 efficacy studies.Their initial development focus is for smoking cessation with parallel development efforts for cocaine, opioid and alcohol use disorders. | Seed / May 19, 2017 | |
|
Aegis Surgical
|
Aegis Surgical Limited will facilitate less invasive placement of aortic valves compared to open heart surgery, on an out-patient basis. | $5.6M / Series B / Jan 04, 2016 | |
Audentes Therapeutics
|
Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients. | $65M / Series C / Oct 13, 2015 | |
|
Aegis Surgical
|
Aegis Surgical Limited will facilitate less invasive placement of aortic valves compared to open heart surgery, on an out-patient basis. | Convertible Note / May 01, 2015 | |
|
Amygdala Neuroscience
|
Amygdala Neurosciences is developing ANS-6637 a new chemical entity with a novel MOA for treating substance use disorder. Based on a mechanism of action in the brain (published in Nature Medicine) that prevents pathophysiologic dopamine surge without changes to basal dopamine, ANS-6637 has the potential to prevent drug seeking behavior, craving andrelapse. In pre-clinical studies, ALDH2 inhibition reduced self-administration, cue- and drug-primed relapse in nicotine, alcohol, cocaine, heroin, methamphetamine and binge eating models and also demonstrated anxiolytic properties in models of stress. ANS-6637 has completed extensive Phase 1 studies and is ready for Phase 2 efficacy studies.Their initial development focus is for smoking cessation with parallel development efforts for cocaine, opioid and alcohol use disorders. | Apr 10, 2015 | |
CardioGen Sciences
|
CardioGen Sciences is a biotechnology company that develops and offers gene therapy solutions for orphan-inherited arrhythmogenic diseases. It was founded in 2014 and is based in Palo Alto, California. | $526K / Seed / Nov 06, 2014 | |
CardioDx
|
CardioDx is a cardiovascular genomic diagnostics company located in Palo Alto, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failures. | $21M / Private Equity / Jul 24, 2014 | |
| See all 14 investments → | |||
Co-Investors
5AM Ventures
1 deal together
Aisling Capital
1 deal together
Alta Partners
1 deal together
Arboretum Ventures
1 deal together
Cormorant Asset Management
1 deal together
Deerfield
1 deal together
About Asset Management Ventures (AMV)
AMV is a venture capital firm investing in early-stage digital health, tech, and life sciences companies.
Asset Management Ventures (AMV) Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Louis Lange
Partner
|
|||
Rich Simoni
Managing Partner
|
|||
Skip Fleshman
Partner
|
|||
|
Pitch Johnson
Founder
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Louis Lange invest in?
Louis Lange invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Funding Round stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Louis Lange last invest?
The most recent investment recorded for Louis Lange closed in Sep 2019. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
